PL394082A1 - Liposomowy preparat zawierający przeciwnowotworową substancję aktywną, sposób jego wytwarzania i zawierająca go kompozycja farmaceutyczna - Google Patents

Liposomowy preparat zawierający przeciwnowotworową substancję aktywną, sposób jego wytwarzania i zawierająca go kompozycja farmaceutyczna

Info

Publication number
PL394082A1
PL394082A1 PL394082A PL39408211A PL394082A1 PL 394082 A1 PL394082 A1 PL 394082A1 PL 394082 A PL394082 A PL 394082A PL 39408211 A PL39408211 A PL 39408211A PL 394082 A1 PL394082 A1 PL 394082A1
Authority
PL
Poland
Prior art keywords
preparation
active substance
pharmaceutical composition
composition containing
weight
Prior art date
Application number
PL394082A
Other languages
English (en)
Other versions
PL226015B1 (pl
Inventor
Jerzy Gubernator
Arkadiusz Kozubek
Piotr Paduszyński
Original Assignee
Wrocławskie Centrum Badań Eit + Spółka Z Ograniczoną Odpowiedzialnością
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wrocławskie Centrum Badań Eit + Spółka Z Ograniczoną Odpowiedzialnością filed Critical Wrocławskie Centrum Badań Eit + Spółka Z Ograniczoną Odpowiedzialnością
Priority to PL394082A priority Critical patent/PL226015B1/pl
Priority to CA2828971A priority patent/CA2828971A1/en
Priority to JP2013555988A priority patent/JP2014506918A/ja
Priority to EP12719451.2A priority patent/EP2680821B1/en
Priority to ES12719451T priority patent/ES2703750T3/es
Priority to CN2012800113206A priority patent/CN103415283A/zh
Priority to AU2012222891A priority patent/AU2012222891A1/en
Priority to PCT/IB2012/051014 priority patent/WO2012117385A2/en
Priority to US14/002,558 priority patent/US20140056968A1/en
Publication of PL394082A1 publication Critical patent/PL394082A1/pl
Publication of PL226015B1 publication Critical patent/PL226015B1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes
    • A61K9/1278—Post-loading, e.g. by ion or pH gradient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Przedmiotem wynalazku jest liposomowy preparat zawierający substancję przeciwnowotworową charakteryzujący się tym, że zawiera substancję aktywną zamkniętą w pęcherzykach liposomowych stanowiących kompozycję składników lipidowych w proporcji 1 część wagowa substancji aktywnej na 5 części wagowych składników lipidowych, korzystnie 1 część wagowa substancji aktywnej na 5 części wagowych składników lipidowych oraz witaminę lub jej pochodną, sposób jego otrzymywania oraz kompozycja zawierająca przedmiotowy preparat.
PL394082A 2011-03-03 2011-03-03 Liposomowy preparat zawierajacy przeciwnowotworowa substancje aktywna, sposob jego wytwarzania i zawierajaca go kompozycja farmaceutyczna PL226015B1 (pl)

Priority Applications (9)

Application Number Priority Date Filing Date Title
PL394082A PL226015B1 (pl) 2011-03-03 2011-03-03 Liposomowy preparat zawierajacy przeciwnowotworowa substancje aktywna, sposob jego wytwarzania i zawierajaca go kompozycja farmaceutyczna
CA2828971A CA2828971A1 (en) 2011-03-03 2012-03-03 Liposome formulation comprising an anti-tumour active substance, method for its preparation and pharmaceutical compositions comprising it
JP2013555988A JP2014506918A (ja) 2011-03-03 2012-03-03 抗腫瘍活性物質を含むリポソーム製剤、その調製のための方法、及び、それを含む医薬組成物
EP12719451.2A EP2680821B1 (en) 2011-03-03 2012-03-03 Liposome formulation comprising an anti-tumour active substance, method for its preparation and pharmaceutical compositions comprising it
ES12719451T ES2703750T3 (es) 2011-03-03 2012-03-03 Formulación liposomal que contiene un compuesto activo antitumoral, método para producirla y composiciones farmacéuticas que la contiene
CN2012800113206A CN103415283A (zh) 2011-03-03 2012-03-03 包含抗肿瘤活性物质的脂质体制剂、它的制备方法以及包含它的药物组合物
AU2012222891A AU2012222891A1 (en) 2011-03-03 2012-03-03 Liposome formulation comprising an anti-tumour active substance, method for its preparation and pharmaceutical compositions comprising it
PCT/IB2012/051014 WO2012117385A2 (en) 2011-03-03 2012-03-03 Liposome formulation comprising an anti-tumour active substance, method for its preparation and pharmaceutical compositions comprising it
US14/002,558 US20140056968A1 (en) 2011-03-03 2012-03-03 Liposome formulation comprising an anti-tumour active substance, method for its preparation and pharmaceutical compositions comprising it

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL394082A PL226015B1 (pl) 2011-03-03 2011-03-03 Liposomowy preparat zawierajacy przeciwnowotworowa substancje aktywna, sposob jego wytwarzania i zawierajaca go kompozycja farmaceutyczna

Publications (2)

Publication Number Publication Date
PL394082A1 true PL394082A1 (pl) 2012-09-10
PL226015B1 PL226015B1 (pl) 2017-06-30

Family

ID=46045037

Family Applications (1)

Application Number Title Priority Date Filing Date
PL394082A PL226015B1 (pl) 2011-03-03 2011-03-03 Liposomowy preparat zawierajacy przeciwnowotworowa substancje aktywna, sposob jego wytwarzania i zawierajaca go kompozycja farmaceutyczna

Country Status (9)

Country Link
US (1) US20140056968A1 (pl)
EP (1) EP2680821B1 (pl)
JP (1) JP2014506918A (pl)
CN (1) CN103415283A (pl)
AU (1) AU2012222891A1 (pl)
CA (1) CA2828971A1 (pl)
ES (1) ES2703750T3 (pl)
PL (1) PL226015B1 (pl)
WO (1) WO2012117385A2 (pl)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA43184A (fr) 2015-11-02 2021-04-14 Fujifilm Corp Composition liposomale et son procédé de production
CA3090483A1 (en) * 2018-02-07 2019-08-15 L.E.A.F. Holdings Group Llc Gamma polyglutamated pemetrexed and uses thereof
JP7514533B2 (ja) * 2018-02-07 2024-07-11 エル．イー．エー．エフ． ホールディングス グループ エルエルシー アルファポリグルタミン酸化テトラヒドロ葉酸およびその使用
JP7490240B2 (ja) * 2018-02-07 2024-05-27 エル．イー．エー．エフ． ホールディングス グループ エルエルシー ガンマポリグルタミン酸化葉酸代謝拮抗薬およびその使用
WO2019157138A1 (en) * 2018-02-07 2019-08-15 L.E.A.F. Holdings Group Llc Alpha polyglutamated pemetrexed and uses thereof
CN111867593A (zh) * 2018-02-07 2020-10-30 L.E.A.F.控股集团公司 α聚谷氨酸化抗叶酸剂及其用途
CN111954529A (zh) * 2018-02-07 2020-11-17 L.E.A.F.控股集团公司 α聚谷氨酸化氨甲蝶呤及其用途
EP3755335A4 (en) * 2018-02-14 2022-06-22 L.E.A.F Holdings Group LLC GAMMA POLYGLUTAMIC TETRAHYDROFOLATES AND THEIR USES
WO2019160733A1 (en) * 2018-02-14 2019-08-22 L.E.A.F. Holdings Group Llc Gamma polyglutamated methotrexate and uses thereof

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
DE2965158D1 (en) * 1979-03-21 1983-05-11 Davy Mckee London Hydroformylation process
US4522803A (en) 1983-02-04 1985-06-11 The Liposome Company, Inc. Stable plurilamellar vesicles, their preparation and use
US5169637A (en) 1983-03-24 1992-12-08 The Liposome Company, Inc. Stable plurilamellar vesicles
US5030453A (en) 1983-03-24 1991-07-09 The Liposome Company, Inc. Stable plurilamellar vesicles
JPS60231608A (ja) * 1984-04-28 1985-11-18 Terumo Corp 膜構造が強化されたリポソ−ム
US5008050A (en) 1984-06-20 1991-04-16 The Liposome Company, Inc. Extrusion technique for producing unilamellar vesicles
US4975282A (en) 1985-06-26 1990-12-04 The Liposome Company, Inc. Multilamellar liposomes having improved trapping efficiencies
CA1338702C (en) 1987-03-05 1996-11-12 Lawrence D. Mayer High drug:lipid formulations of liposomal- antineoplastic agents
IL91664A (en) 1988-09-28 1993-05-13 Yissum Res Dev Co Ammonium transmembrane gradient system for efficient loading of liposomes with amphipathic drugs and their controlled release
US5527528A (en) 1989-10-20 1996-06-18 Sequus Pharmaceuticals, Inc. Solid-tumor treatment method
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
EP0543871A1 (en) 1990-08-08 1993-06-02 Liposome Technology, Inc. Stable doxorubicin/liposome composition
EP0546951A1 (en) 1991-12-13 1993-06-16 The Liposome Company, Inc. Combination of liposome encapsulated antineoplastic agents, such as doxorubicin with colony stimulating factors
CA2132711C (en) * 1992-03-23 2005-02-08 Aquilar Rahman Liposome encapsulated paclitaxel and a method of using the same
JPH06254379A (ja) 1993-03-08 1994-09-13 Taisho Pharmaceut Co Ltd 安定なリポソーム水懸濁液
EP0750910A4 (en) * 1994-03-11 1997-07-09 Yoshitomi Pharmaceutical PREPARATION OF LIPOSOMES
DE4432378A1 (de) * 1994-09-12 1996-03-14 Bayer Ag Injizierbare liposomale Arzneizubereitungen
US5580899A (en) 1995-01-09 1996-12-03 The Liposome Company, Inc. Hydrophobic taxane derivatives
US6262054B1 (en) * 1996-02-01 2001-07-17 Sloan-Kettering Institute Of Cancer Research Combination therapy method for treating breast cancer using edatrexate
US5919815A (en) 1996-05-22 1999-07-06 Neuromedica, Inc. Taxane compounds and compositions
US6090407A (en) 1997-09-23 2000-07-18 Research Development Foundation Small particle liposome aerosols for delivery of anti-cancer drugs
US6146659A (en) * 1998-07-01 2000-11-14 Neopharm, Inc. Method of administering liposomal encapsulated taxane
PL190078B1 (pl) 1998-08-24 2005-10-31 Inst Farmaceutyczny Liposomowy preparat mitoksantronu, sposób jego wytwarzania i przeciwnowotworowa kompozycja farmaceutyczna zawierająca ten preparat
PL190077B1 (pl) 1998-08-24 2005-10-31 Inst Farmaceutyczny Liposomowy preparat doksorubicyny, sposób jego wytwarzania oraz przeciwnowotworowa kompozycja farmaceutyczna zawierająca ten preparat
MXPA02012817A (es) 2000-06-30 2004-07-30 Inex Pharmaceuticals Inc Drogas antineoplasicas liposomales y uso de las mismas.
ATE475411T1 (de) * 2001-10-03 2010-08-15 Celator Pharmaceuticals Inc Liposomenladung mit metallionen
US20040176381A1 (en) * 2003-03-06 2004-09-09 Walsh Michael J. Methotrexate compliance packaging
JP2007524412A (ja) * 2004-01-22 2007-08-30 イムノメディクス， インコーポレイテッド 葉酸コンジュゲートおよびコンプレックス
EP2382996B1 (en) * 2005-02-18 2015-01-14 The University of Tokushima Lipid film structure containing a polyoxyalkylene chain-containing lipid derivative.
CN1772303A (zh) * 2005-10-25 2006-05-17 朱宏 恶性肿瘤磁热疗用纳米磁粉－抗体靶向药物
EP3590503A1 (en) * 2006-10-12 2020-01-08 The University of Queensland Compositions and methods for modulating immune responses
US20080206139A1 (en) * 2006-11-03 2008-08-28 The Penn State Research Foundation Delivery system for diagnostic and therapeutic agents
US8329220B2 (en) * 2007-08-24 2012-12-11 Aegis Therapeutics, Llc Controlled release formulations

Also Published As

Publication number Publication date
AU2012222891A1 (en) 2013-09-19
WO2012117385A2 (en) 2012-09-07
JP2014506918A (ja) 2014-03-20
US20140056968A1 (en) 2014-02-27
EP2680821B1 (en) 2018-08-01
CN103415283A (zh) 2013-11-27
PL226015B1 (pl) 2017-06-30
ES2703750T3 (es) 2019-03-12
CA2828971A1 (en) 2012-09-07
WO2012117385A3 (en) 2013-02-28
EP2680821A2 (en) 2014-01-08

Similar Documents

Publication Publication Date Title
PL394082A1 (pl) Liposomowy preparat zawierający przeciwnowotworową substancję aktywną, sposób jego wytwarzania i zawierająca go kompozycja farmaceutyczna
IL284535A (en) Lipids for lipid nanoparticle delivery of active agents
MX2016007067A (es) Microcapsulas lipidicas que comprenden de preferencia un retinoide y composicion que las contiene, su procedimiento de preparacion y su uso en dermatologia.
MY184381A (en) Stable formulations of lipids and liposomes
WO2011115684A3 (en) Lipid vesicle compositions and methods of use
MX386005B (es) Composicion farmaceutica que contiene farmaco anionico, y metodo de preparacion para la misma.
IN2014DN05866A (pl)
MX2015012200A (es) Composiciones de oxaliplatino en liposomas para la terapia contra el cancer.
BR112014024903A2 (pt) anticorpos biespecíficos contra tweak humanao e il17 humana e seus usos
CR11623A (es) Compuestos
PT3083556T (pt) Lípidos e composições lipídicas para a entrega de agentes ativos
MX360391B (es) Composiciones liposomales combinadas para terapia contra el cancer.
MX351453B (es) Composiciones de liberacion sostenida a base de lipidos anfipaticos.
BR112014009087A2 (pt) formulações de etanercept estabilizadas com xilitol
MX377244B (es) Formulacion arn para inmunoterapia.
AR092372A1 (es) Formulaciones de liposomas, uso y metodo de tratamiento
EA201390203A1 (ru) Способы получения тубулизинов
BR112013017382A2 (pt) métodos para preparação de glicoesfingolipídios e usos destes
MX2018012161A (es) Lipidos y composiciones novedosas para el suministro de terapeuticos.
MX2015012199A (es) Composiciones de cisplatino liposomal para la terapia contra el cancer.
BR112015000229A2 (pt) formulações aquosas estáveis de etanercept
PE20110642A1 (es) Formulaciones antifungicas topicas a base de terbinafina y compuestos similares a terbinafina y metodos de uso
CO6920294A2 (es) Derivados de estra-1,3,5(10),16-tetraen-3-carboxamida, procedimientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparación de medicamentos
NZ702472A (en) Oil/water-emulsion-type topical compositions containing a retinoid
CY1118461T1 (el) Φαρμακευτικες συνθεσεις που περιλαμβανουν αναστολεα αρωματασης